GC
SLS icon

Guggenheim Capital’s SELLAS Life Sciences SLS Stock Holding History

Guggenheim Capital’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-12
Closed -$5K – 2811
2017
Q4 		$5K Sell
12
-1
-8% -$484 ﹤0.01% 2701
2017
Q3 		$7K Buy
13
+4
+44% +$2.64K ﹤0.01% 2791
2017
Q2 		$7K Hold
9
– – ﹤0.01% 2818
2017
Q1 		$8K Buy
+9
New +$14.9K ﹤0.01% 2823

Other funds holding SLS

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Guggenheim Capital's SLS Position: Q1 2018 in Review

Guggenheim Capital sold out of SELLAS Life Sciences (SLS) in Q1 2018, closing a stake of 12 shares — an estimated $5K sold.

Guggenheim Capital first reported a position in SLS in Q1 2017 and held it in 4 quarters. The position peaked at $8K in Q1 2017. 16 funds tracked by Wall St. Rank hold SLS as of Q1 2018.

  • Guggenheim Capital reported no remaining SELLAS Life Sciences position as of Q1 2018 after selling out during the quarter.
  • Guggenheim Capital sold 12 SELLAS Life Sciences shares in Q1 2018, an estimated $5K.
  • Guggenheim Capital first reported a position in SELLAS Life Sciences in Q1 2017 and held it in 4 quarters.
  • Guggenheim Capital's SELLAS Life Sciences position peaked at $8K in Q1 2017.
  • 16 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2018.

Based on Guggenheim Capital's 13F filing for Q1 2018, filed 15 May 2018.